BLACK DIAMOND THERAPEUTICS I's ticker is BDTX and the CUSIP is 09203E105. A total of 68 filers reported holding BLACK DIAMOND THERAPEUTICS I in Q3 2022. The put-call ratio across all filers is 0.96 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6 | -93.5% | 2 | -88.9% | 0.00% | – |
| Q2 2023 | $92 | -70.9% | 18 | -89.3% | 0.00% | – |
| Q1 2023 | $316 | +1875.0% | 168 | +1766.7% | 0.00% | – |
| Q4 2022 | $16 | – | 9 | -96.9% | 0.00% | – |
| Q3 2022 | $0 | – | 290 | +705.6% | 0.00% | – |
| Q2 2022 | $0 | -100.0% | 36 | -99.8% | 0.00% | – |
| Q1 2022 | $41,000 | – | 14,658 | +162766.7% | 0.00% | – |
| Q4 2021 | $0 | – | 9 | 0.0% | 0.00% | – |
| Q3 2021 | $0 | -100.0% | 9 | -100.0% | 0.00% | – |
| Q2 2021 | $4,393,000 | -91.3% | 360,429 | -82.8% | 0.00% | -100.0% |
| Q1 2021 | $50,734,000 | -4.7% | 2,091,288 | +25.9% | 0.00% | -20.0% |
| Q4 2020 | $53,256,000 | +26.0% | 1,661,657 | +18.9% | 0.01% | +25.0% |
| Q3 2020 | $42,252,000 | -29.7% | 1,397,652 | -1.9% | 0.00% | -42.9% |
| Q2 2020 | $60,076,000 | +51.6% | 1,424,935 | -10.3% | 0.01% | +40.0% |
| Q1 2020 | $39,620,000 | – | 1,588,010 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| NEA Management Company, LLC | 3,449,845 | $8,487,000 | 0.44% |
| Hawkeye Capital Management, LLC | 243,009 | $598,000 | 0.33% |
| Boxer Capital, LLC | 2,014,858 | $4,957,000 | 0.31% |
| Newtyn Management, LLC | 520,000 | $1,279,000 | 0.24% |
| Artal Group S.A. | 1,646,517 | $4,050,000 | 0.22% |
| DAFNA Capital Management LLC | 313,600 | $771,000 | 0.21% |
| RA Capital Management | 2,589,904 | $6,371,000 | 0.17% |
| Bellevue Group AG | 4,717,113 | $11,605,000 | 0.16% |
| MPM BioImpact LLC | 239,888 | $590,000 | 0.16% |
| K2 PRINCIPAL FUND, L.P. | 507,652 | $1,249,000 | 0.14% |